Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 known ✓ | P22748 | 4/20 | 0.35 |
| ▸ | CA1 known ✓ | P00915 | 2/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.35 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL21269387 | 0.87 | CA4 (0.40) | CA4FFAR3HDAC3HDAC1HDAC2 | |
| Potassium Ion SCHEMBL104872 | 0.84 | CA4 (0.37) | CA4FFAR3HDAC3HDAC1HDAC2 | |
| SCHEMBL105435 | 0.84 | FFAR3 (0.41) | CA4FFAR3HDAC3HDAC1HDAC2 | |
| SCHEMBL724527 | 0.83 | FFAR3 (0.33) | CA4FFAR3HDAC3HDAC1HDAC2 | |
| Potassium Ion SCHEMBL107736 | 0.81 | CA4 (0.35) | CA4FFAR3HDAC3HDAC1HDAC2 | |
| Potassium Ion SCHEMBL21269182 | 0.81 | CA4 (0.35) | CA4FFAR3HDAC3HDAC1HDAC2 | |
| Lithium Ion SCHEMBL21268800 | 0.81 | FFAR3 (0.39) | CA4FFAR3HDAC3HDAC1HDAC2 | |
| SCHEMBL717123 | 0.81 | FFAR3 (0.39) | CA4FFAR3HDAC3HDAC1HDAC2 | |
| SCHEMBL17433672 | 0.78 | FFAR3 (0.36) | CA4FFAR3HDAC3HDAC1HDAC2 | |
| SCHEMBL21269015 | 0.78 | FFAR3 (0.36) | CA4FFAR3HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210735-A1 | PREVENTION, REDUCTION, OR AMELIORATION OF OLD PERSON SMELL | FIRMENICH SA (CH) | 2023-07-06 | — | — | US | claimed |
| EP-4164587-A1 | PREVENTION, REDUCTION, OR AMELIORATION OF OLD PERSON SMELL | Firmenich SA (CH) | 2023-04-19 | — | — | EP | claimed |
| WO-2021250130-A1 | PREVENTION, REDUCTION, OR AMELIORATION OF OLD PERSON SMELL | FIRMENICH SA (CH) | 2021-12-16 | — | — | WO | claimed |
| CN-107602809-B | High-solid-content aqueous polyurethane dispersion liquid based on aminocarboxylate and sulfamate simultaneously | 温州大学 | 2020-05-22 | — | — | CN | claimed |
| EP-2575807-B1 | FORMULATION BASED ON SULPIRIDE AND A SYNERGISTIC HOMEOPATHIC COMPOSITION FOR TREATMENT OF DEPRESSIVE SYNDROME | NOVAK MAJA (HR) | 2014-02-19 | — | — | EP | claimed |
| EP-2575807-A1 | FORMULATION BASED ON SULPIRIDE AND A SYNERGISTIC HOMEOPATHIC COMPOSITION FOR TREATMENT OF DEPRESSIVE SYNDROME | Novak, Maja (HR) | 2013-04-10 | — | — | EP | claimed |
| WO-2011148203-A1 | FORMULATION BASED ON SULPIRIDE AND A SYNERGISTIC HOMEOPATHIC COMPOSITION FOR TREATMENT OF DEPRESSIVE SYNDROME | NOVAK MAJA (HR) | 2011-12-01 | — | — | WO | claimed |
| EP-0434940-B1 | N-oxygenated arylpyrrole, insecticidal, acaricidal and nematicidal agents | AMERICAN CYANAMID CO (US) | 1996-05-29 | — | — | EP | claimed |
| US-4902819-A | Preparation of sodium diethyl oxalacetate | HOECHST CELANESE CORPORATION (US) | 1990-02-20 | — | — | US | claimed |
| EP-4680608-A1 | 2,6-DIHYDRO-7H-PYRAZOLO[3,4-C]PYRIDIN-7-ONE DERIVATIVES AS ANTI-MALARIAL AGENTS | MMV Medicines for Malaria Venture (CH) | 2026-01-21 | — | — | EP | disclosed |
| US-20240208990-A1 | SPIRO-COMPOUNDS AND COMPOSITIONS INCLUDING THE SAME | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2024-06-27 | — | — | US | disclosed |
| EP-4347602-A1 | SPIRO-COMPOUNDS AND COMPOSITIONS INCLUDING THE SAME | Solventum Intellectual Properties Company (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20230210735-A1 | PREVENTION, REDUCTION, OR AMELIORATION OF OLD PERSON SMELL | FIRMENICH SA (CH) | 2023-07-06 | — | — | US | disclosed |
| EP-4164587-A1 | PREVENTION, REDUCTION, OR AMELIORATION OF OLD PERSON SMELL | Firmenich SA (CH) | 2023-04-19 | — | — | EP | disclosed |
| EP-0520573-A1 | Cyclic imide derivatives | GLAXO INC. (US) | 1992-12-30 | — | — | EP | disclosed |
| US-4737585-A | Process for the preparation of sodium amoxycillin | ANTIBIOTICOS S.A. (ES) | 1988-04-12 | — | — | US | disclosed |
| EP-0220925-A1 | A process for the preparation of sodium amoxycillin | Antibioticos, S.A. (ES) | 1987-05-06 | — | — | EP | disclosed |
| EP-0125276-A1 | NEW CHELATE FORMING BISQUINOLINE COMPOUNDS AND PROCESSES FOR RECOVERING METALS | HÖGBERG, Sverker (SE) | 1984-11-21 | — | — | EP | disclosed |
| WO-1984001946-A1 | NEW CHELATE FORMING BISQUINOLINE COMPOUNDS AND PROCESSES FOR RECOVERING METALS | HOEGBERG SVERKER | 1984-05-24 | — | — | WO | disclosed |
| US-4277476-A | ANTI-ANOXIA AND PSYCHOTROPIC AGENTS | SYNTHELABO (FR) | 1981-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208990-A1 | SPIRO-COMPOUNDS AND COMPOSITIONS INCLUDING THE SAME | REN, PKD1, SAV1 | CA4 591/4885CA1 429/4885FFAR3 1869/4885 |
| US-20230210735-A1 | PREVENTION, REDUCTION, OR AMELIORATION OF OLD PERSON SMELL | ACHE, RBP4, LPO | CA4 576/4885CA1 695/4885FFAR3 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.